M&A Deal Summary

Sanofi Acquires Kiadis Pharma

On May 26, 2021, Sanofi acquired life science company Kiadis Pharma

Acquisition Highlights
  • This is Sanofi’s 15th transaction in the Life Science sector.
  • This is Sanofi’s 1st transaction in the Netherlands.

M&A Deal Summary
Date 2021-05-26
Target Kiadis Pharma
Sector Life Science
Buyer(s) Sanofi
Deal Type Going Private

Target

Kiadis Pharma

Amsterdam, Netherlands
Kiadis Pharma is a clinical stage biopharmaceutical company pioneering a proprietary cell-based, personalized therapy for patients with blood cancers and related disorders, an area of significant unmet medical need.Kiadis Pharma’s unique and powerful platform technology has led to an initial experimental product, ATIR™, which has already been clinically tested on sixty patients. Kiadis Pharma is based in Amsterdam, Netherlands.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Sanofi

Paris, France
Category Company
Founded 1994
Sector Life Science
Employees86,088
Revenue 46.4B EUR (2023)
DESCRIPTION

Sanofi is a French multinational pharmaceutical company headquartered in Paris, France, the world's fourth-largest by prescription sales. Sanofi was founded in 1994 and is based in Paris, France.

DEAL STATS #
Overall 24 of 27
Sector (Life Science) 15 of 18
Type (Going Private) 2 of 2
Country (Netherlands) 1 of 1
Year (2021) 2 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-01-11 Kymab

Cambridge, United Kingdom

Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics with a focus on immune-mediated diseases and immuno-oncology using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab’s IntelliSelect Transgenic platforms contain a full diversity of human antibodies, making them the most comprehensive antibody platforms available. Kymab was founded in 2010 and is based in Cambridge, United Kingdom.

Buy $1.5B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-08-03 Translate Bio

Lexington, Massachusetts, United States

Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Translate Bio was founded in 2011 and is based in Lexington, Massachusetts.

Buy $3.2B
Mergr

Product

Company

Legal